Just - Evotec Biologics

29 articles about Just - Evotec Biologics

• 

  Evotec, Sernova Striving for Functional Diabetes Cure

  5/17/2022

  Evotec and Sernova partnered to develop an implantable induced pluripotent stem cell (iPSC)-based beta cell replacement therapy that can be used to treat both type 1 and 2 diabetes patients.

• Tubulis Closes €60 Million Series B Financing to Accelerate its ADC Pipeline and Expand its Breadth of Platform Technologies

  5/3/2022

  May 3, 2022 09:00 UTC Tubulis announced the successful completion of a €60 million Series B financing led by Andera Partners with participation from new investors Evotec and Fund+.

• Evotec completes acquisition of Just Biotherapeutics

  7/3/2019

  Evotec SE announced that the strategic transaction to acquire Just Biotherapeutics, signed on 20 May 2019, has been completed.

• Just Biotherapeutics and Teva Enter an Agreement for the Design and Development of a High Productivity (HP) Biomanufacturing Process

  6/28/2019

  Just Biotherapeutics, Inc. (Just), an integrated design company focused on technologies for accelerating the development and manufacture of biotherapeutics, announced today that they have entered into an agreement with Teva for the design and development of a high productivity (HP) biomanufacturing process.

• 

  Evotec Diversifies into Biologics with $90 Million Acquisition of Just Biotherapeutics

  5/22/2019

  The deal will grow Evotec's business into a comprehensive offering including biologics in therapeutic areas such as oncology, CNS, pain, inflammation, metabolics and infectious diseases.

• Evotec SE to acquire Just Biotherapeutics, Inc.

  5/21/2019

  Evotec SE announced today the signing of a definitive agreement under which Evotec will acquire Just Biotherapeutics, Inc. ("Just.Bio") based in Seattle, WA, USA for up to US$ 90 m (approx. EUR 81 m; EUR/$ fx rate of 1.117) including potential performance-based earn-out components expected within the next three years.

• Evotec jump-starts biologics with acquisition of Just Biotherapeutics

  5/20/2019

  Evotec SE announced the signing of a definitive agreement under which Evotec will acquire Just Biotherapeutics, Inc. ("Just.Bio"), for up to $ 90 m including potential performance-based earn-out components expected within the next three years.

• ATUM and Just Biotherapeutics Team Up to Accelerate Drug Discovery

  2/21/2018

  ATUM today announced a patent licensing agreement giving Just Biotherapeutics access to the company’s Leap-In cell line development tools.

• Just Biotherapeutics Secures $14 Million Series A2 Funding To Build Laboratory, Pilot Plant And GMP Capabilities

  7/25/2016